CheckMate-901 trial

Opdivo Beats Chemo in First-Line Bladder Cancer, But Keytruda-Padcev Combo Looms Large (ESMO 2023)

ESMO 2023: LBA7 Bladder cancer has presented a unique challenge for immunotherapies, with Bristol Myers Squibb’s Opdivo making strides, but ...